Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TScan Therapeutics Inc TCRX

Healthcare Biotechnology
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual... see more

Recent & Breaking News (NDAQ:TCRX)

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire November 11, 2022

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 9, 2022

TScan Therapeutics Announces Upcoming Virtual Investor Event

GlobeNewswire November 7, 2022

TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 3, 2022

TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire October 5, 2022

TScan Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 22, 2022

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

GlobeNewswire September 12, 2022

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 7, 2022

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

GlobeNewswire August 10, 2022

TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

GlobeNewswire August 3, 2022

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

GlobeNewswire July 11, 2022

TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

GlobeNewswire July 7, 2022

TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

GlobeNewswire June 22, 2022

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

GlobeNewswire May 31, 2022

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

GlobeNewswire May 19, 2022

TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

GlobeNewswire May 12, 2022

TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones

GlobeNewswire May 9, 2022

TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 2, 2022